APO Research
Talk to an analyst

APO RESEARCH · REPORT

Orally Administered Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Orally Administered Vaccine Market Outlook and Growth Opportunities 2026

21 December 2025197 pages

Choose your research edition.

Industry ResearchOrally Administered Vaccine Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Orally Administered Vaccine Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Orally Administered Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orally Administered Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Orally Administered Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Orally Administered Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Orally Administered Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Orally Administered Vaccine market include Lanzhou Institute, Sanofi, Merck, GSK, Tiantan Biological, Valneva, Vabiotech, Shanghai United Cell and Serum Institute, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Orally Administered Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Orally Administered Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orally Administered Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Orally Administered Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Orally Administered Vaccine Segment by Company

Lanzhou Institute

Sanofi

Merck

GSK

Tiantan Biological

Valneva

Vabiotech

Shanghai United Cell

Serum Institute

PaxVax

Panacea Biotec Ltd

Halfkin Bio-Pharmaceuticals

EuBiologics

Bio-Med

Bibcol

Orally Administered Vaccine Segment by Type

Rotavirus Vaccine

Oral Polio Vaccine

Cholera Vaccine

Other

Orally Administered Vaccine Segment by Application

Public

Private

Orally Administered Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Orally Administered Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Orally Administered Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Orally Administered Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Orally Administered Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orally Administered Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orally Administered Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orally Administered Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Orally Administered Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Orally Administered Vaccine industry.

Chapter 3: Detailed analysis of Orally Administered Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Orally Administered Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Orally Administered Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Orally Administered Vaccine Industry Trends Table 2. Orally Administered Vaccine Industry Drivers Table 3. Orally Administered Vaccine Industry Opportunities and Challenges Table 4. Orally Administered Vaccine Industry Restraints Table 5. Global Orally Administered Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Orally Administered Vaccine Revenue Share by Company (2021-2026) Table 7. Global Orally Administered Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Orally Administered Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Orally Administered Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Orally Administered Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Orally Administered Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Orally Administered Vaccine Company, Product Type & Application Table 13. Global Orally Administered Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Orally Administered Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rotavirus Vaccine Table 18. Significant Companies of Oral Polio Vaccine Table 19. Significant Companies of Cholera Vaccine Table 20. Significant Companies of Other Table 21. Global Orally Administered Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Orally Administered Vaccine Sales Volume by Type (2021-2026) & (k units) Table 23. Global Orally Administered Vaccine Sales Volume by Type (2027-2032) & (k units) Table 24. Global Orally Administered Vaccine Sales Volume Share by Type (2021-2026) Table 25. Global Orally Administered Vaccine Sales Volume Share by Type (2027-2032) Table 26. Global Orally Administered Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Orally Administered Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Orally Administered Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Orally Administered Vaccine Sales Value Share by Type (2021-2026) Table 30. Global Orally Administered Vaccine Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Public Table 32. Significant Companies of Private Table 33. Global Orally Administered Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Orally Administered Vaccine Sales Volume by Application (2021-2026) & (k units) Table 35. Global Orally Administered Vaccine Sales Volume by Application (2027-2032) & (k units) Table 36. Global Orally Administered Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Orally Administered Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Orally Administered Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Orally Administered Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Orally Administered Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Orally Administered Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Orally Administered Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Orally Administered Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Orally Administered Vaccine Sales by Region (2021-2026) & (k units) Table 45. Global Orally Administered Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Orally Administered Vaccine Sales by Region (2027-2032) & (k units) Table 47. Global Orally Administered Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Orally Administered Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Orally Administered Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Orally Administered Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Orally Administered Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Orally Administered Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Orally Administered Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Orally Administered Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Orally Administered Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Orally Administered Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 58. Global Orally Administered Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 60. Global Orally Administered Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Orally Administered Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Orally Administered Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Orally Administered Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Orally Administered Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Lanzhou Institute Company Information Table 66. Lanzhou Institute Business Overview Table 67. Lanzhou Institute Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Lanzhou Institute Orally Administered Vaccine Product Portfolio Table 69. Lanzhou Institute Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Sanofi Orally Administered Vaccine Product Portfolio Table 74. Sanofi Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Merck Orally Administered Vaccine Product Portfolio Table 79. Merck Recent Development Table 80. GSK Company Information Table 81. GSK Business Overview Table 82. GSK Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. GSK Orally Administered Vaccine Product Portfolio Table 84. GSK Recent Development Table 85. Tiantan Biological Company Information Table 86. Tiantan Biological Business Overview Table 87. Tiantan Biological Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Tiantan Biological Orally Administered Vaccine Product Portfolio Table 89. Tiantan Biological Recent Development Table 90. Valneva Company Information Table 91. Valneva Business Overview Table 92. Valneva Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Valneva Orally Administered Vaccine Product Portfolio Table 94. Valneva Recent Development Table 95. Vabiotech Company Information Table 96. Vabiotech Business Overview Table 97. Vabiotech Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Vabiotech Orally Administered Vaccine Product Portfolio Table 99. Vabiotech Recent Development Table 100. Shanghai United Cell Company Information Table 101. Shanghai United Cell Business Overview Table 102. Shanghai United Cell Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Shanghai United Cell Orally Administered Vaccine Product Portfolio Table 104. Shanghai United Cell Recent Development Table 105. Serum Institute Company Information Table 106. Serum Institute Business Overview Table 107. Serum Institute Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Serum Institute Orally Administered Vaccine Product Portfolio Table 109. Serum Institute Recent Development Table 110. PaxVax Company Information Table 111. PaxVax Business Overview Table 112. PaxVax Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. PaxVax Orally Administered Vaccine Product Portfolio Table 114. PaxVax Recent Development Table 115. Panacea Biotec Ltd Company Information Table 116. Panacea Biotec Ltd Business Overview Table 117. Panacea Biotec Ltd Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio Table 119. Panacea Biotec Ltd Recent Development Table 120. Halfkin Bio-Pharmaceuticals Company Information Table 121. Halfkin Bio-Pharmaceuticals Business Overview Table 122. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio Table 124. Halfkin Bio-Pharmaceuticals Recent Development Table 125. EuBiologics Company Information Table 126. EuBiologics Business Overview Table 127. EuBiologics Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. EuBiologics Orally Administered Vaccine Product Portfolio Table 129. EuBiologics Recent Development Table 130. Bio-Med Company Information Table 131. Bio-Med Business Overview Table 132. Bio-Med Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Bio-Med Orally Administered Vaccine Product Portfolio Table 134. Bio-Med Recent Development Table 135. Bibcol Company Information Table 136. Bibcol Business Overview Table 137. Bibcol Orally Administered Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Bibcol Orally Administered Vaccine Product Portfolio Table 139. Bibcol Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Orally Administered Vaccine Distributors List Table 143. Orally Administered Vaccine Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Orally Administered Vaccine Product Image Figure 2. Global Orally Administered Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orally Administered Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Orally Administered Vaccine Sales (2021-2032) & (k units) Figure 5. Global Orally Administered Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Orally Administered Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rotavirus Vaccine Image Figure 10. Oral Polio Vaccine Image Figure 11. Cholera Vaccine Image Figure 12. Other Image Figure 13. Global Orally Administered Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Orally Administered Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Orally Administered Vaccine Sales Volume Share by Type (2021-2032) Figure 16. Global Orally Administered Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Orally Administered Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Orally Administered Vaccine Sales Value Share by Type (2021-2032) Figure 19. Public Image Figure 20. Private Image Figure 21. Global Orally Administered Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Orally Administered Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Orally Administered Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Orally Administered Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Orally Administered Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Orally Administered Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Orally Administered Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Orally Administered Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Orally Administered Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Orally Administered Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Orally Administered Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Orally Administered Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Orally Administered Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Orally Administered Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Orally Administered Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Orally Administered Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Orally Administered Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Orally Administered Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Orally Administered Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Orally Administered Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Orally Administered Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Orally Administered Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Orally Administered Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Rotavirus Vaccine
  • Oral Polio Vaccine
  • Cholera Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Lanzhou Institute
  • Sanofi
  • Merck
  • GSK
  • Tiantan Biological
  • Valneva
  • Vabiotech
  • Shanghai United Cell
  • Serum Institute
  • PaxVax
  • Panacea Biotec Ltd
  • Halfkin Bio-Pharmaceuticals
  • EuBiologics
  • Bio-Med
  • Bibcol

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Orally Administered Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Orally Administered Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Orally Administered Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Orally Administered Vaccine Market Dynamics
  1. 2.1 Orally Administered Vaccine Industry Trends
  2. 2.2 Orally Administered Vaccine Industry Drivers
  3. 2.3 Orally Administered Vaccine Industry Opportunities and Challenges
  4. 2.4 Orally Administered Vaccine Industry Restraints
3 Orally Administered Vaccine Market by Company
  1. 3.1 Global Orally Administered Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Orally Administered Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Orally Administered Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Orally Administered Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Orally Administered Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Orally Administered Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Orally Administered Vaccine Company Product Type and Application
  8. 3.8 Global Orally Administered Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Orally Administered Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Orally Administered Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Orally Administered Vaccine Market by Type
  1. 4.1 Orally Administered Vaccine Type Introduction
  2. 4.1.1 Rotavirus Vaccine
  3. 4.1.2 Oral Polio Vaccine
  4. 4.1.3 Cholera Vaccine
  5. 4.1.4 Other
  6. 4.2 Global Orally Administered Vaccine Sales Volume by Type
  7. 4.2.1 Global Orally Administered Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Orally Administered Vaccine Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Orally Administered Vaccine Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Orally Administered Vaccine Sales Value by Type
  11. 4.3.1 Global Orally Administered Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Orally Administered Vaccine Sales Value by Type (2021-2032)
  13. 4.3.3 Global Orally Administered Vaccine Sales Value Share by Type (2021-2032)
5 Orally Administered Vaccine Market by Application
  1. 5.1 Orally Administered Vaccine Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Orally Administered Vaccine Sales Volume by Application
  5. 5.2.1 Global Orally Administered Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Orally Administered Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Orally Administered Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Orally Administered Vaccine Sales Value by Application
  9. 5.3.1 Global Orally Administered Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Orally Administered Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Orally Administered Vaccine Sales Value Share by Application (2021-2032)
6 Orally Administered Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Orally Administered Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orally Administered Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Orally Administered Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Orally Administered Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Orally Administered Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Orally Administered Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Orally Administered Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Orally Administered Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Orally Administered Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Orally Administered Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Orally Administered Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Orally Administered Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Orally Administered Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Orally Administered Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Orally Administered Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Orally Administered Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Orally Administered Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Orally Administered Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Orally Administered Vaccine Sales Value Share by Country, 2025 VS 2032
7 Orally Administered Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Orally Administered Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Orally Administered Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Orally Administered Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Orally Administered Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Orally Administered Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Orally Administered Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Orally Administered Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Orally Administered Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Orally Administered Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Orally Administered Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Orally Administered Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lanzhou Institute
  2. 8.1.1 Lanzhou Institute Company Information
  3. 8.1.2 Lanzhou Institute Business Overview
  4. 8.1.3 Lanzhou Institute Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Lanzhou Institute Orally Administered Vaccine Product Portfolio
  6. 8.1.5 Lanzhou Institute Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Orally Administered Vaccine Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Orally Administered Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Orally Administered Vaccine Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Tiantan Biological
  26. 8.5.1 Tiantan Biological Company Information
  27. 8.5.2 Tiantan Biological Business Overview
  28. 8.5.3 Tiantan Biological Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Tiantan Biological Orally Administered Vaccine Product Portfolio
  30. 8.5.5 Tiantan Biological Recent Developments
  31. 8.6 Valneva
  32. 8.6.1 Valneva Company Information
  33. 8.6.2 Valneva Business Overview
  34. 8.6.3 Valneva Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Valneva Orally Administered Vaccine Product Portfolio
  36. 8.6.5 Valneva Recent Developments
  37. 8.7 Vabiotech
  38. 8.7.1 Vabiotech Company Information
  39. 8.7.2 Vabiotech Business Overview
  40. 8.7.3 Vabiotech Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Vabiotech Orally Administered Vaccine Product Portfolio
  42. 8.7.5 Vabiotech Recent Developments
  43. 8.8 Shanghai United Cell
  44. 8.8.1 Shanghai United Cell Company Information
  45. 8.8.2 Shanghai United Cell Business Overview
  46. 8.8.3 Shanghai United Cell Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai United Cell Orally Administered Vaccine Product Portfolio
  48. 8.8.5 Shanghai United Cell Recent Developments
  49. 8.9 Serum Institute
  50. 8.9.1 Serum Institute Company Information
  51. 8.9.2 Serum Institute Business Overview
  52. 8.9.3 Serum Institute Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Serum Institute Orally Administered Vaccine Product Portfolio
  54. 8.9.5 Serum Institute Recent Developments
  55. 8.10 PaxVax
  56. 8.10.1 PaxVax Company Information
  57. 8.10.2 PaxVax Business Overview
  58. 8.10.3 PaxVax Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 PaxVax Orally Administered Vaccine Product Portfolio
  60. 8.10.5 PaxVax Recent Developments
  61. 8.11 Panacea Biotec Ltd
  62. 8.11.1 Panacea Biotec Ltd Company Information
  63. 8.11.2 Panacea Biotec Ltd Business Overview
  64. 8.11.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio
  66. 8.11.5 Panacea Biotec Ltd Recent Developments
  67. 8.12 Halfkin Bio-Pharmaceuticals
  68. 8.12.1 Halfkin Bio-Pharmaceuticals Company Information
  69. 8.12.2 Halfkin Bio-Pharmaceuticals Business Overview
  70. 8.12.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio
  72. 8.12.5 Halfkin Bio-Pharmaceuticals Recent Developments
  73. 8.13 EuBiologics
  74. 8.13.1 EuBiologics Company Information
  75. 8.13.2 EuBiologics Business Overview
  76. 8.13.3 EuBiologics Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 EuBiologics Orally Administered Vaccine Product Portfolio
  78. 8.13.5 EuBiologics Recent Developments
  79. 8.14 Bio-Med
  80. 8.14.1 Bio-Med Company Information
  81. 8.14.2 Bio-Med Business Overview
  82. 8.14.3 Bio-Med Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bio-Med Orally Administered Vaccine Product Portfolio
  84. 8.14.5 Bio-Med Recent Developments
  85. 8.15 Bibcol
  86. 8.15.1 Bibcol Company Information
  87. 8.15.2 Bibcol Business Overview
  88. 8.15.3 Bibcol Orally Administered Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Bibcol Orally Administered Vaccine Product Portfolio
  90. 8.15.5 Bibcol Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Orally Administered Vaccine Value Chain Analysis
  2. 9.1.1 Orally Administered Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Orally Administered Vaccine Sales Mode & Process
  6. 9.2 Orally Administered Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Orally Administered Vaccine Distributors
  9. 9.2.3 Orally Administered Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst